Physician profile
Brett E Swenson
NPI 1902891880
$1,598.99
in general payments reported to CMS, 2019-2025
23 companies · $61.67 in 2025
The $61.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $371 · 2021: $290 · 2022: $83.51 · 2023: $179 · 2024: $77.31 · 2025: $61.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $336.92 | 2019-2023 | Livalo |
| Astrazeneca Pharmaceuticals Lp | $329.81 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $145.35 | 2021-2024 | Qulipta, Ubrelvy |
| Antares Pharma, INC. | $110.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.62 | 2019-2022 | |
| Lilly USA, LLC | $87.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $67.89 | 2020-2021 | |
| Genentech USA, INC. | $48.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.37 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $38.59 | 2021 | |
| Arbor Pharmaceuticals, INC. | $38.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.91 | 2019 | |
| Novo Nordisk INC | $29.69 | 2019-2020 | |
| Medtronic, INC. | $25.54 | 2025 | Intellis Adaptivestim |
| Abbott Laboratories | $22.23 | 2025 | Proclaim |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $21.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.69 | 2023 | Qelbree |
| Xeris Pharmaceuticals, INC. | $19.68 | 2023 | Keveyis |
| Axonics, INC. | $19.61 | 2023 | Axonics |
| Biohaven Pharmaceuticals, INC. | $15.01 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.33 | 2024 | Unithroid |
| Regeneron Healthcare Solutions, INC. | $12.65 | 2019 | |
| Eisai INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Swenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.